

doi 2282

---

**ERRATUM**

## 2006 drug approvals: finding the niche

*Joanna Owens*

*Nature Reviews Drug Discovery* 6, 99–101 (2007); doi:10.1038/nrd2247

The article incorrectly states that Cephalon's drug Sparlon is already approved for the treatment of wakefulness in adults and has been on the market in the United States for 7 years. The article should have stated that Cephalon's Provigil, which contains the same active ingredient (modafinil) as Sparlon but in different doses, is approved for the treatment of wakefulness in adults only and has been on the market in the United States for 9 years.